TNFRSF18 and central nervous system cancer: The effect of an anti-GITR agonist in the setting of murine glioma has not been investigated prior to this study, although GITR activation is an appealing strategy for its dual stimulatory influence on effector T cells and suppressive effect on Tregs [8, 10–13, 15, 17].